相关实验视频

Updated: May 24, 2025

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

已定义的细胞重编程的雄激素受体活性前列腺癌的神经内分泌前列腺癌

Shan Li¹, Kai Song², Huiyun Sun^1,3

¹Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA, 98109, USA.

bioRxiv : the preprint server for biology

|March 3, 2025

概括

研究人员使用特定因素将雄激素受体阳性前列腺癌 (ARPC) 转化为神经内分泌前列腺癌 (NEPC). 这项研究揭示了ASCL1和NeuroD1如何沉默AR信号,并推动NEPC的发展,为治疗耐药性提供了洞察力.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
遗传学是一个遗传学.

背景情况:

神经内分泌前列腺癌 (NEPC) 通常由通过神经内分泌转基因分化 (NEtD) 从雄激素受体阳性前列腺癌 (ARPC) 发展.
这种NEtD是针对针对雄激素受体 (AR) 信号传导的治疗方法的抵抗机制.
目前研究NEtD驱动器及其对AR信号的影响的模型有限.

研究的目的:

为研究前列腺癌中NEtD开发一个模型系统.
确定推动ARPC转换为NEPC的关键因素.
了解AR信号抑制和NEPC血统建立背后的分子机制.

主要方法:

利用基因定义的细胞重编程策略将ARPC转换为NEPC.
雇佣了包括ASCL1和NeuroD1在内的候选因素,以诱导转差异化.
在ARPC到NEPC血统转换过程中分析了转录组和表观组的变化.
研究了RE-1沉默转录因子 (REST) 在NEPC开发中的作用.

主要成果:

通过使用特定的候选因子,成功将ARPC转换为AR独立的NEPC.
确定了ASCL1和NeuroD1先驱因子在抑制AR表达和信号传递中的关键作用.
证明ASCL1和NeuroD1可以在AR调节元件中重塑染色质.
在急性血统转换过程中阐明了动态的转录和表观遗传学景观.
区分了ASCL1/NeuroD1与REST无活化在NEPC谱系建立和MHC I调制中的作用.

结论:

ASCL1和NeuroD1是前列腺癌中NEtD的关键驱动因素,通过染色体重塑来静止AR信号来起作用.
这项研究为研究NEtD及其相关的治疗耐药性提供了一个新的模型.
研究结果提供了对NEPC发育和潜在治疗点的生物机制的关键见解.

关键词:

在ASCL1中,这是一个神经D1D1的过程.受体受体是受体的受体.细胞重新编程的细胞重编程.血统的可塑性血统的可塑性神经内分泌前列腺癌前列腺癌.神经内分泌转基因差异化

更多相关视频

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

A Rapid Filter Insert-based 3D Culture System for Primary Prostate Cell Differentiation

A Rapid Filter Insert-based 3D Culture System for Primary Prostate Cell Differentiation

Published on: February 13, 2017

相关概念视频

Introduction to Nuclear Reprogramming

Introduction to Nuclear Reprogramming

Nuclear reprogramming is the process of switching gene expression of one cell type to that of another cell type, usually from a differentiated cell state to an undifferentiated cell state. Differentiation occurs during processes such as development and morphogenesis, tissue regeneration, and malignancy. Cells can also be artificially induced to reprogram their gene expression by techniques such as nuclear transfer, induced pluripotency, and cell fusion. Such techniques have many applications in...

Somatic to iPS Cell Reprogramming

Somatic to iPS Cell Reprogramming

Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012...

Methods of Nuclear Reprogramming

Methods of Nuclear Reprogramming

Nuclear reprogramming is a process of transforming one cell type into an unrelated cell type by epigenetic changes that alter the cell’s original gene expression pattern. Such epigenetic changes force cells to express a different set of genes, which play a significant role in inducing transformation into other cell types. Nuclear reprogramming offers applications in reproductive cloning for livestock propagation and regenerative medicine — developing patient-specific cells for...